Current prostate cancer screening and treatment strategies may not support a holistic nationwide program.
Black ethnic group
United Kingdom.
cancer specialists
culturally care
diagnosis
health care disparities
patient relationship
prostate cancer
screening
treatment protocols
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
revised:
15
05
2022
received:
05
02
2022
accepted:
16
05
2022
pubmed:
2
6
2022
medline:
12
7
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
The diversity of the United Kingdom population and its health care personnel makes it unique for research into evidence-based prostate cancer screening and management strategies. Therefore, ensuring that appropriate systems and services are available to enhance treatment support for men with underlying risk factors should be a priority for health care providers. More efforts are also needed to ensure the representation of men of Black ethnic origin and underserved populations in future prostate cancer research used to inform clinical guidelines.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2858-2864Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 American Cancer Society.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52. doi:10.1016/j.eururo.2019.08.005
Are you at risk? Prostate Cancer UK. Published August 2020. Accessed September 21, 2020. https://prostatecanceruk.org/prostate-information/are-you-at-risk
Prostate cancer statistics. Cancer Research UK. Published 2020. Accessed October 15, 2020. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer
Prostate cancer. National Health Service. Published June 12, 2018. Accessed September 21, 2020. https://www.nhs.uk/conditions/prostate-cancer
NHS Cancer Programme. National Health Service. Published 2019. Accessed December 7, 2021. https://www.england.nhs.uk/wp-content/uploads/2019/12/200124-Quarterly-Report-Q3-Final-22.pdf
Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581. doi:10.1136/bmj.k3581
Mallett S, Halligan S, Matthew Thompson GP, Collins GS, Altman DG. Interpreting diagnostic accuracy studies for patient care. BMJ. 2012;345(7871):e3999. doi:10.1136/bmj.e3999
Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. doi:10.3389/fpubh.2017.00307
Public Health England. PSA test for prostate cancer. Guidelines. Published January 2020. Accessed December 7, 2021. https://www.guidelines.co.uk/cancer/phe-psa-prostate-cancer-test-guideline-/252826.article
Swift A, Heale R, Twycross A. What are sensitivity and specificity? Evid Based Nurs. 2020;23(1):2-4. doi:10.1136/ebnurs-2019-103,225
Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence. Published 2019. Accessed December 8, 2021. https://www.nice.org.uk/guidance/ng131
Prostate-specific antigen (PSA) test. National Cancer Institute. Published 2017. Accessed September 19, 2020. https://www.cancer.gov/types/prostate/psa-fact-sheet
Chen N, Zhou Q. The evolving Gleason grading system. Chin J Cancer Res. 2016;28(1):58-64. doi:10.3978/j.issn.1000-9604.2016.02.04
Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017.
Albertsen PC. The evolving paradigm of prostate cancer screening. JAMA Netw Open. 2019;2(8):e198392. doi:10.1001/jamanetworkopen.2019.8392
Gilbert N. The pros and cons of screening. Nature. 2020;579(7800):S2-S4. doi:10.1038/d41586-020-00841-8
Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort. JAMA Netw Open. 2021;4(5):e219444. doi:10.1001/jamanetworkopen.2021.9444
Rönningås U, Fransson P, Holm M, Wennman-Larsen A. Prostate-specific antigen (PSA) and distress: a cross-sectional nationwide survey in men with prostate cancer in Sweden. BMC Urol. 2019;19(1):1-8. doi:10.1186/s12894-019-0493-1
Kim JY, Yu JH, Sung LH, Cho DY, Kim HJ, Yoo SJ. Usefulness of the Prostate Health Index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. BMC Urol. 2021;21(1):1-10. doi:10.1186/s12894-021-00897-2
Huang D, Yang X, Wu Y, et al. Cost-effectiveness analysis of Prostate Health Index in decision making for initial prostate biopsy. Front Oncol. 2020;10:2618. doi:10.3389/fonc.2020.565382
Schulze A, Christoph F, Sachs M, et al. Use of the Prostate Health Index and density in 3 outpatient centers to avoid unnecessary prostate biopsies. Urol Int. 2020;104(3-4):181-186. doi:10.1159/000506262
Tosoian JJ, Druskin SC, Andreas D, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis. 2017;20(2):228-233. doi:10.1038/pcan.2016.72
Srivastava S, Koay EJ, Borowsky AD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349-358. doi:10.1038/s41568-019-0142-8
Kilpeläinen TP, Tammela TLJ, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. 2011;47(18):2698-2705. doi:10.1016/j.ejca.2011.06.055
Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur Urol. 2018;74(2):204-210. doi:10.1016/j.eururo.2017.12.028
Eklund M, Nordström T, Aly M, et al. The Stockholm-3 (STHLM3) model can improve prostate cancer diagnostics in men aged 50-69 yr compared with current prostate cancer testing. Eur Urol Focus. 2018;4(5):707-710. doi:10.1016/j.euf.2016.10.009
Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Cancer Council Australia. Accessed December 10, 2021. https://wiki.cancer.org.au/australia/Guidelines:PSA_Testing#_ga=2.107442242.1718052127.1639138488-872086933.1639138488
Prostate-specific antigen (PSA) test. National Cancer Institute. Accessed December 10, 2021. https://www.cancer.gov/types/prostate/psa-fact-sheet
Projects and policies: consensus on PSA testing. Prostate Cancer UK. Published 2021. Accessed November 21, 2021. https://prostatecanceruk.org/about-us/projects-and-policies/consensus-on-psa-testing
Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. doi:10.1136/bmj.k3519
UK National Screening Committee. GOV.UK. Accessed December 9, 2021. https://www.gov.uk/government/organisations/uk-national-screening-committee
Elwenspoek MMC, Sheppard AL, McInnes MDF, et al. Comparison of multiparametric magnetic resonance imaging and targeted biopsy with systematic biopsy alone for the diagnosis of prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198427. doi:10.1001/jamanetworkopen.2019.8427
White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (PHI) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2017;21(1):78-84. doi:10.1038/s41391-017-0008-7
Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6(2):74. doi:10.1177/1756287213513488
Bouttell J, Teoh J, Chiu PK, et al. Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong. PLoS One. 2019;14(4):e0215279. doi:10.1371/journal.pone.0215279
Aladwani M, Lophatananon A, Ollier W, Muir K. Prediction models for prostate cancer to be used in the primary care setting: a systematic review. BMJ Open. 2020;10(7):e034661. doi:10.1136/bmjopen-2019-034661
Kim L, Boxall N, George A, et al. Clinical utility and cost modelling of the PHI test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study. BMC Med. 2020;18(1):1-9. doi:10.1186/s12916-020-01548-3
Carthon B, Sibold HC, Blee SD, Pentz R. Prostate cancer: community education and disparities in diagnosis and treatment. Oncologist. 2021;26(7):537. doi:10.1002/onco.13749
Watkinson RE, Sutton M, Turner AJ. Ethnic inequalities in health-related quality of life among older adults in England: secondary analysis of a national cross-sectional survey. Lancet Public Health. 2021;6(3):e145-e154. doi:10.1016/s2468-2667(20)30287-5
The health of people from ethnic minority groups in England. The King's Fund. Accessed May 2, 2022. https://www.kingsfund.org.uk/publications/health-people-ethnic-minority-groups-england
Delon C, Brown KF, Payne NWS, Kotrotsios Y, Vernon S, Shelton J. Differences in cancer incidence by broad ethnic group in England, 2013-2017. Br J Cancer. 2022. Published online March 2, 2022. doi:10.1038/s41416-022-01718-5
Cancer registration statistics, England: first release, 2016. Office for National Statistics. Published January 25, 2018. Accessed October 7, 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2016
Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack men. JAMA. 2018;320(23):2479-2481. doi:10.1001/jama.2018.11716
Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5(7):975-983. doi:10.1001/jamaoncol.2019.0826
Oladeru OT, Perni S, Williams B. Improving care for the overlooked in oncology: incarcerated patients. Lancet Oncol. 2019;20(10):1342-1344. doi:10.1016/s1470-2045(19)30577-7
Douglas E, Waller J, Duffy SW, Wardle J. Socioeconomic inequalities in breast and cervical screening coverage in England: are we closing the gap? J Med Screen. 2016;23(2):98. doi:10.1177/0969141315600192
Severe mental illness (SMI): inequalities in cancer screening uptake report. GOV.UK. Accessed December 16, 2021. https://www.gov.uk/government/publications/severe-mental-illness-inequalities-in-cancer-screening-uptake/severe-mental-illness-smi-inequalities-in-cancer-screening-uptake-report
Robb K, Wardle J, Stubbings S, et al. Ethnic disparities in knowledge of cancer screening programmes in the UK. J Med Screen. 2010;17(3):125-131. doi:10.1258/jms.2010.009112
Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol. 2019;9:238. doi:10.3389/fonc.2019.00238
Williamson P. Reducing inequalities in BME patient experience of cancer care. NHS England. Published January 9, 2020. Accessed December 17, 2021. https://www.england.nhs.uk/blog/reducing-inequalities-bme-cancer-care/
Huerto R, Lindo E. Minority patients benefit from having minority doctors, but that's a hard match to make. The Conversation. Published February 13, 2020. Accessed April 21, 2022. https://theconversation.com/minority-patients-benefit-from-having-minority-doctors-but-thats-a-hard-match-to-make-130504
Chinegwundoh FI. The relationship between Black men with prostate cancer and their health-care providers. Nat Rev Urol. 2021;18(12):701-702. doi:10.1038/s41585-021-00525-6
Zelic R, Garmo H, Zugna D, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180-188. doi:10.1016/j.eururo.2019.09.027
Brandão A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci. 2020;21(14):1-23. doi:10.3390/ijms21145036
Clinckaert A, Devos G, Roussel E, Joniau S. Risk stratification tools in prostate cancer, where do we stand? Transl Androl Urol. 2021;10(1):128-118. doi:10.21037/tau-20-1211
Leary A, Brocksom J, Endacott R, et al. The specialist nursing workforce caring for men with prostate cancer in the UK. Int J Urol Nurs. 2016;10(1):5-13. doi:10.1111/ijun.12104
Making the case for clinical nurse specialists. Prostate Cancer UK. Published 2019. Accessed December 17, 2021. https://prostatecanceruk.org/for-health-professionals/making-the-case-for-clinical-nurse-specialists
Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883-895. doi:10.1001/jama.2018.0154
Bamidele OO, McGarvey HE, Lagan BM, Chinegwundoh F, Ali N, McCaughan E. “Hard to reach, but not out of reach”: barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research. Eur J Cancer Care. 2019;28(2):e12977. 10.1111/ecc.12977